The Novel Coronavirus and Haemostatic abnormalities pathophysiology clinical manifesttations and treatment recommendations
dc.citation.doi | 10.1007/978-3-030-59261-5 | |
dc.citation.epage | 180 | |
dc.citation.spage | 173 | |
dc.contributor.author | Susan Louw | |
dc.contributor.author | Barry Jacobson | |
dc.contributor.author | Elizabeth Mayne | |
dc.contributor.author | Tracey Wiggill | |
dc.date.accessioned | 2023-02-28T09:38:16Z | |
dc.date.available | 2023-02-28T09:38:16Z | |
dc.department | Molecular Medicine and Haematology | |
dc.description.abstract | The COVID-19 pandemic, caused by the SARS-C0V-2 virus, was initially considered and managed in a similar manner to the previous SARS epidemic as they are both caused by coronaviruses. What has now become apparent is that a major cause of morbidity and mortality in COVID-19 is abnormal thrombosis. This thrombosis occurs on a macro- and microvascular level and is unique to this disease. The virus has been demonstrated in the endothelium of the pulmonary alveoli and as such is thought to contribute to the devastating respiratory complications encountered. D-dimer concentrations are frequently raised in COVID to levels not frequently seen previously. The optimal anticoagulation treatment in COVID remains to be determined, and the myriad of pathophysiologic effects caused by this virus in the human host have also yet to be fully elucidated. | |
dc.faculty | Faculty of Health Sciences | |
dc.identifier.citation | Louw S, Jacobson BF, Mayne ES, Wiggill TM. The Novel Coronavirus and Haemostatic Abnormalities: Pathophysiology, Clinical Manifestations, and Treatment Recommendations. Adv Exp Med Biol. 2021;1321:173-180. doi:10.1007/978-3-030-59261-5_15 | |
dc.identifier.issn | 0065-2598 | |
dc.identifier.uri | https://hdl.handle.net/10539/34707 | |
dc.journal.title | Advances in experimental medicine and biology | |
dc.journal.volume | 1321 | |
dc.rights | © The Author(s), under exclusive license to Springer Nature Switzerland AG 2021 | |
dc.school | School of Pathology | |
dc.subject | COVID-19 | |
dc.subject | SARS-CoV-2 | |
dc.subject | Coagulopathy | |
dc.subject | Thrombosis | |
dc.subject | Biomarkers | |
dc.subject | Treatment | |
dc.subject.other | SDG-3: Good health and well-being | |
dc.title | The Novel Coronavirus and Haemostatic abnormalities pathophysiology clinical manifesttations and treatment recommendations | |
dc.type | Article |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- Journal.pdf
- Size:
- 243.18 KB
- Format:
- Adobe Portable Document Format
- Description:
- Journal